<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894581</url>
  </required_header>
  <id_info>
    <org_study_id>13-1420</org_study_id>
    <secondary_id>U54HD058155-05</secondary_id>
    <nct_id>NCT01894581</nct_id>
  </id_info>
  <brief_title>Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women</brief_title>
  <official_title>Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The United States has the highest prevalence of obesity among all countries surveyed in 2012
      by the Organization for Economic Cooperation and Development. Maternal obesity is linked with
      anovulation, menstrual cycle abnormalities, subfertility, fetal loss, obstetrical
      complications and congenital anomalies. Changes in reproductive hormones and diminished
      oocyte quality have also been demonstrated. A gap of knowledge exists as the mechanisms
      underlying these harmful effects are poorly understood and no specific treatments exist.

      This proposal will test the hypothesis that dietary omega-3 fatty acids (FA) will improve the
      output of hypothalamicpituitary- ovarian axis in obese women. The investigators will perform
      paired assessments before and after supplementation in 10 obese and 10 normal weight women.
      To test the pituitary and hypothalamic output, the investigators will examine the luteinizing
      hormone (LH) and follicle-stimulating hormone (FSH) responsiveness during frequent blood
      sampling. To test the corpus luteum function, the investigators will examine urinary
      reproductive hormones (E1c, estrone conjugates, and pregnanediol glucuronide (Pdg)) over an
      entire menstrual cycle. The investigators ultimate goal is to collect preliminary data for an
      adequately powered randomized control trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Average LH Pulse Amplitude</measure>
    <time_frame>10 minute intervals during 8 hour blood sampling studies. Subjects will undergo two menstrual cycles of study, one prior to dietary supplementation and one after supplementation.</time_frame>
    <description>To test the pituitary and hypothalamic output, we examined LH secretion (unstimulated and in response to gonadotropin-releasing hormone (GnRH) stimulation) during 8-hour blood sampling studies at 10 min intervals. The primary outcome measure is the change in the average LH pulse amplitude for each patient from baseline to after supplementation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Obesity</condition>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>Obese Women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LOVAZA</intervention_name>
    <description>Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.</description>
    <arm_group_label>Obese Women</arm_group_label>
    <arm_group_label>Normal Weight</arm_group_label>
    <other_name>Omega-3-acid ethyl esters</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH</intervention_name>
    <description>An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.</description>
    <arm_group_label>Obese Women</arm_group_label>
    <arm_group_label>Normal Weight</arm_group_label>
    <other_name>Gonadorelin (GnRH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-42 at study entry

          2. Regular menstrual cycles every 25-40 days

          3. BMI at least 30 kg/m2 (obese) or between 18.5 and 25 kg/m2 (normal)

          4. Good general health

          5. Prolactin and thyroid-stimulating hormone (TSH) within normal laboratory ranges at
             screening, baseline hemoglobin &gt;11 gm/dl.

        Exclusion Criteria:

          1. Diagnosis of polycystic ovary syndrome (by ultrasound or hyperandrogenic symptoms)

          2. Fish or seafood allergy or hypersensitivity (e.g., anaphylactic reaction) to
             omega-3-acid ethyl esters or any component of the formulation

          3. Coagulopathy or receiving therapeutic anticoagulation (due to potential for
             interaction with omega-3 FA)

          4. History of chronic disease affecting hormone production, metabolism or clearance
             (including diabetes mellitus)

          5. Abnormal renal or liver function at screening

          6. Current use of thiazolidinediones or metformin (known to interact with reproductive
             hormones)

          7. Use of hormones affecting hypothalamic output (HPO) axis (such as hormonal
             contraceptives) within three months of entry

          8. Strenuous exercise (&gt;4 hours of intense physical activity per week)

          9. Pregnancy

         10. Breast-feeding

         11. Current active attempts to conceive

         12. History of significant recent weight loss or gain
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Polotsky, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2016</results_first_posted>
  <last_update_submitted>December 8, 2016</last_update_submitted>
  <last_update_submitted_qc>December 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 regularly menstruating obese and normal-weight women were recruited from the community through campus-wide advertisements.</recruitment_details>
      <pre_assignment_details>Potential participants were screened out if they had polycystic ovary syndrome, allergies to seafood, used medications known to affect reproductive hormones, used exogenous sex steroids within the last 3 months, exercised vigorously more than 4 hours weekly, or were attempting pregnancy. Eligible subjects then had a baseline physical examination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Obese</title>
          <description>BMI &gt;= 30 kg/m2</description>
        </group>
        <group group_id="P2">
          <title>Normal Weight</title>
          <description>BMI 18-25 kg/m2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Obese</title>
          <description>BMI &gt;= 30 kg/m2</description>
        </group>
        <group group_id="B2">
          <title>Normal Weight</title>
          <description>BMI 18-25 kg/m2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="1.2"/>
                    <measurement group_id="B2" value="28.4" spread="1.2"/>
                    <measurement group_id="B3" value="31.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="1.5"/>
                    <measurement group_id="B2" value="21.8" spread=".5"/>
                    <measurement group_id="B3" value="31.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Average LH Pulse Amplitude</title>
        <description>To test the pituitary and hypothalamic output, we examined LH secretion (unstimulated and in response to gonadotropin-releasing hormone (GnRH) stimulation) during 8-hour blood sampling studies at 10 min intervals. The primary outcome measure is the change in the average LH pulse amplitude for each patient from baseline to after supplementation.</description>
        <time_frame>10 minute intervals during 8 hour blood sampling studies. Subjects will undergo two menstrual cycles of study, one prior to dietary supplementation and one after supplementation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese</title>
            <description>BMI &gt;= 30 kg/m2</description>
          </group>
          <group group_id="O2">
            <title>Normal Weight</title>
            <description>BMI 18-25 kg/m2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Average LH Pulse Amplitude</title>
          <description>To test the pituitary and hypothalamic output, we examined LH secretion (unstimulated and in response to gonadotropin-releasing hormone (GnRH) stimulation) during 8-hour blood sampling studies at 10 min intervals. The primary outcome measure is the change in the average LH pulse amplitude for each patient from baseline to after supplementation.</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.04" spread=".2"/>
                    <measurement group_id="O2" value=".4" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During approximately one menstrual cycle.</time_frame>
      <desc>Adverse event data were collected for the duration of the participant's participation, which was approximately one menstrual cycle. Data were from all subjects were collected from June of 2013 to February of 2015.</desc>
      <group_list>
        <group group_id="E1">
          <title>Obese</title>
          <description>BMI &gt;= 30 kg/m2</description>
        </group>
        <group group_id="E2">
          <title>Normal Weight</title>
          <description>BMI 18-25 kg/m2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alex Polotsky</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-2001</phone>
      <email>alex.polotsky@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

